ENZC (Enzolytics) Stock Based Compensation: $1.37 Mil (TTM As of Jun. 2011)


What is Enzolytics Stock Based Compensation?

Enzolytics ENZC -12.50% Stock Based Compensation is $1.37 Mil as of Jun. 2011.

Enzolytics's Stock Based Compensation for the three months ended in Jun. 2011 was $0.03 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2011 was $1.37 Mil.

Enzolytics Stock Based Compensation Related Terms

Enzolytics Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Enzolytics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enzolytics Stock Based Compensation Chart

Enzolytics Annual Data
Trend Dec07 Jul08 Dec09 Dec10
Stock Based Compensation
0.00 0.00 0.35 2.58

Enzolytics Quarterly Data
Sep07 Dec07 Apr08 Jul08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.92 0.54 0.80 0.00 0.03

Enzolytics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2011 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.37 Mil.

What does a Stock Based Compensation of $1.37 Mil mean?
Enzolytics (ENZC) has a Stock Based Compensation of $1.37 Mil as of Jun. 2011. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Enzolytics and its competitors.
Is Enzolytics' Stock Based Compensation too high?
Enzolytics' current Stock Based Compensation is $1.37 Mil.
How does Enzolytics' Stock Based Compensation compare to competitors?
Enzolytics' Stock Based Compensation of $1.37 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Enzolytics and its competitors. Enzolytics's current Stock Based Compensation is $1.37 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enzolytics stock overvalued right now?
Enzolytics (ENZC) has a current Stock Based Compensation of $1.37 Mil. The current Stock Based Compensation is $1.37 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Enzolytics (ENZC), the current Stock Based Compensation is $1.37 Mil as of Jun. 2011. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Enzolytics Business Description

Address 1101 Raintree Circle, Suite 130, Allen, TX, USA, 75013
Enzolytics Inc is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. The company is committed to creating drugs for the good health of mankind. ENZC's flagship compound, ITV-1, is a suspension of Inactivated Pepsin Fragment (IPF), which studies have shown is effective in the treatment of HIV. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system. IPF is a platform technology that can be used to facilitate a broad range of applications. It is free from neurological, gastrointestinal and hematological side effects seen in the anti-retrovirals in use.